Journey Medical (DERM) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NeOnc Technologies (NTHI) has outperformed Journey Medical (DERM) over the past year, losing 46.2% versus a loss of 55.8%. Journey Medical is the larger company by market cap ($93.2 million vs $90.9 million), about 1.0 times the size. Journey Medical converts more of its revenue into profit, with a net margin of -18.5% versus -155404.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | NTHI |
|---|---|---|
| Share price | $3.30 | $3.15 |
| Market cap | $93.16M | $90.88M |
| 1-day change | -7.04% | -9.48% |
| YTD return | -57.20% | -61.91% |
| 1-year return | -55.76% | -46.25% |
| 5-year return | -61.13% | — |
| EPS (TTM) | $-0.18 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $61.86M | $39.99K |
| Revenue growth (YoY) | +10.20% | -51.82% |
| Net income (latest FY) | $-11.43M | $-62.15M |
| Gross margin | 66.17% | — |
| Operating margin | -13.21% | -145637.52% |
| Net margin | -18.48% | -155404.38% |
| 52-week high | $9.56 | $11.38 |
| 52-week low | $3.21 | $2.50 |
| Distance from 52-week high | -65.46% | -72.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +286.36% | +439.68% |
| Average volume | 190.39K | 187.23K |
| Shares outstanding | 22.23M | 28.85M |
| Employees | 58 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Journey Medical is more profitable, keeping -18.5 cents of every revenue dollar as net income versus -155404.4 cents for NeOnc Technologies.
- Journey Medical grew revenue faster in its latest fiscal year (+10.20% vs -51.82%).
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
DERM vs NTHI FAQ
Which is bigger, Journey Medical or NeOnc Technologies?
Journey Medical (DERM) is larger, with a market capitalization of $93.16M compared with $90.88M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, DERM or NTHI?
NTHI returned -46.25% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.